Advances in pharmacologic strategies for cancer cachexia

Bibliography

• Evans WJ, Morley JE, Argilés J, et al. Cachexia: a new definition. Clin Nutr 2008;276:793-9
   Web of Science ®Google Scholar
• Anker SD, Coats AJ, Morley JE, et al. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle 2014;5:1-3
   Google Scholar
• Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489-95
   PubMed Web of Science ®Google Scholar
• Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle 2014;5:253-9
   PubMed Web of Science ®Google Scholar
• Martin L, Senesse P, Gioulbasanis I, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol 2015;33:90-9
   PubMed Web of Science ®Google Scholar
• Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 2013;10:90-9
   PubMed Web of Science ®Google Scholar
• Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008;33:997-1006
   PubMed Web of Science ®Google Scholar
• Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013;31:1539-47
   PubMed Web of Science ®Google Scholar
• Di Sebastiano KM, Mourtzakis M. A critical evaluation of body composition modalities used to assess adipose and skeletal muscle tissue in cancer. Appl Physiol Nutr Metab 2012;37:811-21
   PubMed Web of Science ®Google Scholar
• Plank LD. Dual-energy X-ray absorptiometry and body composition. Curr Opin Clin Nutr Metab Care 2005;8:305-9
   PubMed Web of Science ®Google Scholar
• Fredrix EW, Saris WH, Soeters PB, et al. Estimation of body composition by bioelectrical impedance in cancer patients. Eur J Clin Nutr 1990;44:749-52
   PubMed Web of Science ®Google Scholar
• Norman K, Stobäus N, Pirlich M, Bosy-Westphal A. Bioelectrical phase angle and impedance vector analysis--clinical relevance and applicability of impedance parameters. Clin Nutr 2012;31:854-61
   PubMed Web of Science ®Google Scholar
• Gupta D, Lammersfeld CA, Vashi PG, et al. Bioelectrical impedance phase angle in clinical practice: implications for prognosis in stage IIIB and IV non-small cell lung cancer. BMC Cancer 2009;9:37
   PubMed Web of Science ®Google Scholar
• Norman K, Stobäus N, Zocher D, et al. Cutoff percentiles of bioelectrical phase angle predict functionality, quality of life, and mortality in patients with cancer. Am J Clin Nutr 2010;92:612-19
   PubMed Web of Science ®Google Scholar
• Brown DJ, McMillan DC, Milroy R. The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer 2005;103:377-82
   PubMed Web of Science ®Google Scholar
• Prado CM, Lieffers JR, Bowthorpe L, et al. Sarcopenia and physical function in overweight patients with advanced cancer. Can J Diet Pract Res 2013;74:69-74
   PubMed Web of Science ®Google Scholar
• Piskorz L, Lesiak T, Brocki M, et al. Biochemical and functional indices of malnutrition in patients with operable, non-microcelullar lung cancer. Nutr Hosp 2011;26:1025-32
   PubMed Web of Science ®Google Scholar
• Kilgour RD, Vigano A, Trutschnigg B, et al. Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Support Care Cancer 2013;2:3261-70
   Web of Science ®Google Scholar
• Kasymjanova G, Correa JA, Kreisman H, et al. Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J Thorac Oncol 2009;4:602-7
   PubMed Web of Science ®Google Scholar
• Maddocks M, Wilcock A. Exploring physical activity level in patients with thoracic cancer: implications for use as an outcome measure. Support Care Cancer 2012;20:1113-16
   PubMed Web of Science ®Google Scholar
• Fouladiun M, Körner U, Gunnebo L, et al. Daily physical-rest activities in relation to nutritional state, metabolism, and quality of life in cancer patients with progressive cachexia. Clin Cancer Res 2007;13:6379-85
   PubMed Web of Science ®Google Scholar
• Bergner M. Quality of life, health status, and clinical research. Med Care 1989;27(3 Suppl):S148-56
   PubMed Web of Science ®Google Scholar
• Boini S, Briançon S, Guillemin F, et al. Impact of cancer occurrence on health-related quality of life: a longitudinal pre-post assessment. Health Qual Life Outcomes 2004;2:4
   PubMedGoogle Scholar
• Ribaudo JM, Cella D, Hahn EA, et al. Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res 2000;9:1137-46
   PubMed Web of Science ®Google Scholar
• Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, et al. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2013;3:CD004310
   PubMed Web of Science ®Google Scholar
• Beller E, Tattersall M, Lumley T, et al. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group. Ann Oncol 1997;8:277-83
   PubMed Web of Science ®Google Scholar
• Vadell C, Seguí MA, Giménez-Arnau JM, et al. Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. Am J Clin Oncol 1998;21:347-51
   PubMed Web of Science ®Google Scholar
• De Conno F, Martini C, Zecca E, et al. Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial. Eur J Cancer 1998;34:1705-9
   PubMed Web of Science ®Google Scholar
• Feliu J, González-Barón M, Berrocal A, et al. Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo-controlled study. Am J Clin Oncol 1992;15:436-40
   PubMed Web of Science ®Google Scholar
• Fietkau R, Riepl M, Kettner H, et al. Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. Eur J Cancer 1997;33:75-9
   PubMed Web of Science ®Google Scholar
• Gebbia V, Testa A, Gebbia N. Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. Br J Cancer 1996;73:1576-80
   PubMed Web of Science ®Google Scholar
• Heckmayr M, Gatzemeier U. Treatment of cancer weight loss in patients with advanced lung cancer. Oncology 1992;49:32-4
   PubMed Web of Science ®Google Scholar
• Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002;20:567-73
   PubMed Web of Science ®Google Scholar
• Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004;22:2469-7
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990;82:1127-32
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Bernath AM, Schaid DJ, et al. Phase III evaluation of 4 doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Oncology 1994;51:2-7
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999;17:3299-306
   PubMed Web of Science ®Google Scholar
• McMillan DC, Simpson JM, Preston T, et al. Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients. Clin Nutr 1994;13:85-9
   PubMed Web of Science ®Google Scholar
• Madeddu C, Dessì M, Panzone F, et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr 2012;31:176-82
   PubMed Web of Science ®Google Scholar
• Schmoll E, Wilke H, Thole R, et al. Megestrol acetate in cancer cachexia. Semin Oncol 1991;18(1 Suppl 2):32-4
   PubMed Web of Science ®Google Scholar
• Schmoll E. Risks and benefits of various therapies for cancer anorexia. Oncology 1992;49:43-5
   PubMed Web of Science ®Google Scholar
• Tchekmedyian NS, Hickman M. Megestrol acetate in cancer anorexia and weight loss. Cancer 1992;69:1268-74
   PubMed Web of Science ®Google Scholar
• Ulutin HC, Arpaci F, Pak Y. Megestrol acetate for cachexia and anorexia in advanced non-small cell lung cancer: a randomized study comparing two different doses. Tumori 2002;88:277-80
   PubMed Web of Science ®Google Scholar
• Macciò A, Madeddu C, Mantovani G. Current pharmacotherapy options for cancer anorexia and cachexia. Expert Opin Pharmacother 2012;13:2453-72
   PubMed Web of Science ®Google Scholar
• Del Fabbro E, Garcia JM, Dev R, et al. Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial. Support Care Cancer 2013;21:2599-607
   PubMed Web of Science ®Google Scholar
• Gullett NP, Hebbar G, Ziegler TR. Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am J Clin Nutr 2010;91:1143S-7S
   PubMed Web of Science ®Google Scholar
• Yeh SS, De Guzman B, Kramer T; M012 Study Group. Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest 2002;122:421-8
   PubMed Web of Science ®Google Scholar
• Storer TW, Woodhouse LJ, Sattler F, et al. A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment. J Clin Endocrinol Metab 2005;90:4474-82
   PubMed Web of Science ®Google Scholar
• Mulligan K, Zackin R, Clark RA, et al. Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2005;165:578-85
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Daar ES, Gertner JM, et al. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004;35:367-75
   PubMed Web of Science ®Google Scholar
• Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998;351:1233-7
   PubMed Web of Science ®Google Scholar
• Pupim LB, Flakoll PJ, Yu C, Ikizler TA. Recombinant human growth hormone improves muscle amino acid uptake and whole-body protein metabolism in chronic hemodialysis patients. Am J Clin Nutr 2005;82:1235-43
   PubMed Web of Science ®Google Scholar
• Dalton JT, Taylor RP, Mohler ML, et al. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr Opin Support Palliat Care 2013;7:345-51
   PubMed Web of Science ®Google Scholar
• Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013;14:335-45
   PubMed Web of Science ®Google Scholar
• Crawford J, Johnston MA, Taylor RP, et al. Enobosarm and lean body mass in patients with non-small cell lung cancer. J Clin Oncol 2014;32(5 Suppl):Abstract 9618
   Google Scholar
• Müller TD, Tschöp MH. Ghrelin - a key pleiotropic hormone-regulating systemic energy metabolism. Endocr Dev 2013;25:91-100
   PubMedGoogle Scholar
• Temel J, Currow D, Fearon K, et al. Anamorelin for the treatment of cancer anorexia-cachexia in patients with advanced NSCLC: results from the pivotal phase III study ROMANA 1and 2. Ann Oncol 2014;Abstract 1483O-PR
   Google Scholar
• Garcia JM, Boccia RV, Graham CD, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol 2015;16:108-16
   PubMed Web of Science ®Google Scholar
• Lundholm K, Daneryd P, Körner U, et al. Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 2004;24:505-12
   PubMed Web of Science ®Google Scholar
• Reid J, Hughes CM, Murray LJ, et al. Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review. Palliat Med 2013;27:295-303
   PubMed Web of Science ®Google Scholar
• Mantovani G, Macciò A, Madeddu C, et al. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med (Berl) 2010;88:85-92
   PubMed Web of Science ®Google Scholar
• Bayliss TJ, Smith JT, Schuster M, et al. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 2011;11:1663-8
   PubMed Web of Science ®Google Scholar
• Ando K, Takahashi F, Motojima S, et al. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol 2013;31:e69-72
   PubMed Web of Science ®Google Scholar
• Hirata H, Tetsumoto S, Kijima T, et al. Favorable responses to tocilizumab in two patients with cancer-related cachexia. J Pain Symptom Manage 2013;46:e9-e13
   PubMed Web of Science ®Google Scholar
• Chasen M, Bhargava R, Hirschman S, et al. Phase II study of OHR/AVR118 in anorexia-cachexia. J Cachexia Sarcopenia Muscle Abstracts of the 7th Cachexia Conference, Kobe/Osaka. Japan, December 9–11, 2013 2013;4:335; Abstract 5-04
   Google Scholar
• Hong DS, Hui D, Bruera E, et al. MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol 2014;15:656-66
   PubMed Web of Science ®Google Scholar
• Mesa RA, Verstovsek S, Gupta V, et al. Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I. Clin Lymphoma Myeloma Leuk 2015;15:214-21
   PubMed Web of Science ®Google Scholar
• Reid J, Mills M, Cantwell M, et al. Thalidomide for managing cancer cachexia. Cochrane Database Syst Rev 2012;4:CD008664
   PubMed Web of Science ®Google Scholar
• Gordon JN, Trebble TM, Ellis RD, et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005;54:540-5
   PubMed Web of Science ®Google Scholar
• Wilkes EA, Selby AL, Cole AT, et al. Poor tolerability of thalidomide in end-stage oesophageal cancer. Eur J Cancer Care (Engl) 2011;20:593-600
   PubMed Web of Science ®Google Scholar
• Mantovani G, Macciò A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Nutrition 2008;24:305-13
   PubMed Web of Science ®Google Scholar
• Stewart Coats AJ, Srinivasan V, Surendran J, et al. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle 2011;2:201-20
   Google Scholar
• Ebner N, Steinbeck L, Doehner W, et al. Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies. J Cachexia Sarcopenia Muscle 2014;5(1):27-34
   PubMedGoogle Scholar
• Thomas DR. Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr 2007;26:389-99
   PubMed Web of Science ®Google Scholar
• Nixon DW, Lawson DH, Kutner M, et al. Hyperalimentation of the cancer patient with protein-calorie undernutrition. Cancer Res 1981;41:2038-45
   PubMed Web of Science ®Google Scholar
• Percival C, Hussain A, Zadora-Chrzastowska S, et al. Providing nutritional support to patients with thoracic cancer: findings of a dedicated rehabilitation service. Respir Med 2013;107:753-61
   PubMed Web of Science ®Google Scholar
• Norton JA, Gorschboth CM, Wesley RA, et al. Fasting plasma amino acid levels in cancer patients. Cancer 1985;56:1181-6
   PubMed Web of Science ®Google Scholar
• Yoshizawa F. Regulation of protein synthesis by branched-chain amino acids in vivo. Biochem Biophys Res Commun 2004;313:417-22
   PubMed Web of Science ®Google Scholar
• Campos-Ferraz PL, Bozza T, Nicastro H, et al. Distinct effects of leucine or a mixture of the branched-chain amino acids (leucine, isoleucine, and valine) supplementation on resistance to fatigue, and muscle and liver-glycogen degradation, in trained rats. Nutrition 2013;29:1388-94
   PubMed Web of Science ®Google Scholar
• Nicastro H, da Luz CR, Chaves DF, et al. Does Branched-Chain Amino Acids Supplementation Modulate Skeletal Muscle Remodeling through Inflammation Modulation? Possible Mechanisms of Action. J Nutr Metab 2012;2012:136937
   PubMedGoogle Scholar
• Eley HL, Russell ST, Tisdale MJ. Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem J 2007;407:113-20
   PubMed Web of Science ®Google Scholar
• Shen WH, Boyle DW, Wisniowski P, et al. Insulin and IGF-I stimulate the formation of the eukaryotic initiation factor 4F complex and protein synthesis in C2C12 myotubes independent of availability of external amino acids. J Endocrinol 2005;185:275-89
   PubMed Web of Science ®Google Scholar
• Cangiano C, Laviano A, Meguid MM, et al. Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. J Natl Cancer Inst 1996;88:550-2
   PubMed Web of Science ®Google Scholar
• Tayek JA, Bistrian BR, Hehir DJ, et al. Improved protein kinetics and albumin synthesis by branched chain amino acid-enriched total parenteral nutrition in cancer cachexia. A prospective randomized crossover trial. Cancer 1986;58:147-57
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Kanemaki T, Tsuji M, et al. Branched-chain amino acid-supplemented nutritional support after gastrectomy for gastric cancer with special reference to plasma amino acid profiles. Nutrition 1990;6:241-5
   PubMed Web of Science ®Google Scholar
• Fitschen PJ, Wilson GJ, Wilson JM, et al. Efficacy of beta-hydroxy-beta-methylbutyrate supplementation in elderly and clinical populations. Nutrition 2013;29:29-36
   PubMed Web of Science ®Google Scholar
• Aversa Z, Bonetto A, Costelli P, et al. Beta-hydroxy-beta-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia. Int J Oncol 2011;38:713-20
   PubMed Web of Science ®Google Scholar
• Murphy RA, Mourtzakis M, Mazurak VC. N-3 polyunsaturated fatty acids: the potential role for supplementation in cancer. Curr Opin Clin Nutr Metab Care 2012;15:246-51
   PubMed Web of Science ®Google Scholar
• Smith GI, Atherton P, Reeds DN, et al. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. Am J Clin Nutr 2011;93:402-12
   PubMed Web of Science ®Google Scholar
• Fetterman JWJr, Zdanowicz MM. Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am J Health Syst Pharm 2009;66:1169-79
   PubMed Web of Science ®Google Scholar
• Finocchiaro C, Segre O, Fadda M, et al. Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. Br J Nutr 2012;108:327-33
   PubMed Web of Science ®Google Scholar
• Murphy RA, Mourtzakis M, Chu QS, et al. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 2011;117:1775-82
   PubMed Web of Science ®Google Scholar
• Sánchez-Lara K, Turcott JG, Juárez-Hernández E, et al. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: Randomised trial. Clin Nutr 2014;33:1017-23
   PubMed Web of Science ®Google Scholar
• Fearon KC, Barber MD, Moses AG, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006;24:3401-7
   PubMed Web of Science ®Google Scholar
• Dewey A, Baughan C, Dean T, et al. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev 2007(1):CD004597
   Google Scholar
• Stephens FB, Constantin-Teodosiu D, Greenhaff PL. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J Physiol 2007;581(Pt 2):431-44
   PubMed Web of Science ®Google Scholar
• Ringseis R, Keller J, Eder K. Mechanisms underlying the anti-wasting effect of L-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies. Eur J Nutr 2013;52:1421-42
   PubMed Web of Science ®Google Scholar
• Gramignano G, Lusso MR, Madeddu C, et al. Efficacy of L-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition 2006;22:136-45
   PubMed Web of Science ®Google Scholar
• Kraft M, Kraft K, Gärtner S, et al. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial. Nutr J 2012;11:52
   PubMed Web of Science ®Google Scholar
• Argilés JM, Busquets S, Stemmler B, et al. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 2014;14:754-62
   PubMed Web of Science ®Google Scholar
• Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008;44:1124-32
   PubMed Web of Science ®Google Scholar
• Mantovani G, Macciò A, Madeddu C, et al. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev 2006;15:1030-4
   PubMed Web of Science ®Google Scholar
• Mantovani G, Macciò A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010;15:200-11
   PubMed Web of Science ®Google Scholar
• Macciò A, Madeddu C, Gramignano G, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 2012;124:417-25
   PubMed Web of Science ®Google Scholar
• Cerchietti LC, Navigante AH, Peluffo GD, et al. Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage 2004;27:85-95
   PubMed Web of Science ®Google Scholar
• Cerchietti LC, Navigante AH, Castro MA. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer 2007;59:14-20
   PubMed Web of Science ®Google Scholar
• Wen HS, Li X, Cao YZ, et al. Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. Chemotherapy 2012;58:461-7
   PubMed Web of Science ®Google Scholar
• Engineer DR, Garcia JM. Leptin in anorexia and cachexia syndrome. Int J Pept 2012;2012:287457
   PubMedGoogle Scholar
• Macciò A, Madeddu C, Massa D, et al. Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients. J Cell Mol Med 2009;13(9B):3951-9
   PubMed Web of Science ®Google Scholar
• Mondello P, Lacquaniti A, Mondello S, et al. Emerging markers of cachexia predict survival in cancer patients. BMC Cancer 2014;14:828
   PubMed Web of Science ®Google Scholar
• Sinclair S, Bouchal SR, Chochinov H, et al. Spiritual care: how to do it. BMJ Support Palliat Care 2012;2:319-27
   PubMedGoogle Scholar